• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Bavarian Nordic

189.90 DKK

-0.31 %

Less than 1K followers

BAVA

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-0.31 %
+4.00 %
-2.96 %
-1.56 %
-0.50 %
+9.67 %
+3.46 %
-26.37 %
+33.14 %

Bavarian Nordic is a biochemistry company. Today, the company specializes in the development, manufacture, and distribution of vaccines against infectious diseases in connection with cancer treatment. In addition, vaccines against other serious diseases such as Ebola and cervical cancer are also being developed. The largest operations are located in Europe and in the U.S. Bavarian Nordic was founded in 1994 and is headquartered in Kvistgaard, Denmark.

Read more
Market cap
15.05B DKK
Turnover
18.24M DKK
Revenue
6.24B
EBIT %
28.89 %
P/E
10.79
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
21.8
2026

Interim report Q2'26

13.11
2026

Interim report Q3'26

Regulatory press release06.07.2026, 09.56

Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprogram

Bavarian Nordic
Regulatory press release06.07.2026, 09.56

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Bavarian Nordic
HCA Morgenbørs 29/06 - Udsigt til kursstigninger og fokus på sektorrotation
Video29.06.2026, 09.16 by
Michael Friis, Rasmus Køjborg

HCA Morgenbørs 29/06 - Udsigt til kursstigninger og fokus på sektorrotation

Udsigt til kursstigninger i Europa fra morgenstunden, fredagens sektorrotation ud af tech samt mildere toner mellem USA og Iran trækker op. Fokus herhjemme på bl.a. Novo Nordisk, Lundbeck og Carlsberg.

Flügger GroupLundbeckCarlsbergBavarian NordicBioMar GroupNovo NordiskBang & Olufsen

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release29.06.2026, 08.36

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Bavarian Nordic
Regulatory press release29.06.2026, 08.36

Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprogram

Bavarian Nordic
Press release29.06.2026, 07.30

Bavarian Nordics chikungunyavaccine er blevet godkendt af de canadiske lægemiddelmyndigheder

Bavarian Nordic
Press release29.06.2026, 07.30

Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine

Bavarian Nordic
HCA Morgenbørs 22/06 - Fredsprocessen er tilbage på sporet og fokus på Novo og Vestas
Video22.06.2026, 09.28 by
Victor Skriver, Michael Friis

HCA Morgenbørs 22/06 - Fredsprocessen er tilbage på sporet og fokus på Novo og Vestas

Udsigt til en flad åbning i Europa, tegn på fredsproces er tilbage på sporet efter bump hen over weekenden. Herhjemme fokus på blandt andet Novo Nordisk og Vestas

Novo NordiskVestas Wind SystemsFLSmidth & Co.Bavarian NordicNordea
Regulatory press release22.06.2026, 08.53

Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprogram

Bavarian Nordic
Regulatory press release22.06.2026, 08.53

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Bavarian Nordic
Regulatory press release15.06.2026, 08.44

Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprogram

Bavarian Nordic
Regulatory press release15.06.2026, 08.44

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Bavarian Nordic
Regulatory press release09.06.2026, 12.49

Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine

Bavarian Nordic
Regulatory press release09.06.2026, 12.49

Bavarian Nordic modtager ny ordre fra regering på koppe-/mpoxvacciner

Bavarian Nordic
Regulatory press release08.06.2026, 08.54

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Bavarian Nordic
Regulatory press release08.06.2026, 08.54

Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprogram

Bavarian Nordic
HCA Morgenbørs 03/06 - Overvejende negative markeder og fokus på Genmab og Novo Nordisk
Video03.06.2026, 09.29 by
Rasmus Køjborg, Victor Skriver

HCA Morgenbørs 03/06 - Overvejende negative markeder og fokus på Genmab og Novo Nordisk

I dagens Morgenbørs kigger vi ind i overvejende negative markeder, hvor USA-Iran konflikten igen synes at skygge for AI-euforien. Fokus herhjemme på Genmab og Novo Nordisk.

Novo NordiskGenmabDanish Aerospace and Defence CompanyHafniaFLSmidth & Co.BioMar GroupSwiss Properties InvestDSVRockwoolAmbuBavarian Nordic
Regulatory press release02.06.2026, 08.11

Bavarian Nordic lancerer næste del af aktietilbagekøbsprogram

Bavarian Nordic
Regulatory press release02.06.2026, 08.11

Bavarian Nordic Launches Next Tranche of Share Buy-Back Program

Bavarian Nordic
Regulatory press release13.05.2026, 21.01

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

Bavarian Nordic